Colorectal Cancer and Quality of Life: A Medicare Advantage Study by Race, Ethnicity, and Language
Journal of Surgical Oncology · 2025
DOI: 10.1002/jso.28005 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Surgical Oncology, 2025. Verfasst von Emna Bakillah und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Ethnicity, Language, Medicare Part C. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMHD NIH HHS, This study was supported by National Institutes of Health., National Institutes of Health.
Abstract (Originalsprache)
Background and Methods Colorectal cancer (CRC) treatment can influence health‐related quality of life (HRQOL). This study examined HRQOL among older adults undergoing CRC treatment, and the conditional effects of race, ethnicity, and primary language. We conducted a retrospective cohort study of Medicare Advantage enrollees ≥ 65 years old who completed the Medicare Health Outcomes Survey (MHOS) (2016−2020). The exposure group answered “Yes” to the current CRC treatment and the control group answered “No.” The primary outcomes were physical component summary (PCS) and mental component summary (MCS) scores. Conditional effects by race and ethnicity were analyzed using interaction terms.
Results
Among 184 486 adults, 676 (0.4%) reported current CRC treatment. Those receiving treatment had significantly lower PCS scores ( β coefficient −1.98, p < 0.001) and lower MCS scores ( β coefficient −0.81, p = 0.018), compared to nontreatment. In the treatment group, Hispanic respondents and Spanish speakers had higher PCS scores ( β coefficient 1.96, p = 0.019 and 3.19, p = 0.023, respectively), and respondents identifying as American Indian or Alaska Native had higher MCS scores ( β coefficient 8.72, p = 0.016).
Conclusion
Individuals receiving CRC treatment exhibit worse HRQOL. Outcomes differed by race and ethnicity. This study suggests the need to invest in targeted interventions to improve overall HRQOL during treatment for CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Surgery, Center for Surgery and Health Economics, Philadelphia, Pennsylvania, USA.
- Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Emergency Medicine, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Gastroenterology, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Förderung
- NIMHD NIH HHS
- This study was supported by National Institutes of Health.
- National Institutes of Health
Zitieren
APA
Bakillah, E., Rosenthal, J. W., Syvyk, S., Wirtalla, C., Sharpe, J., Merchant, R. M., Mehta, S. J., Guerra, C. E., & Kelz, R. (2025). Colorectal Cancer and Quality of Life: A Medicare Advantage Study by Race, Ethnicity, and Language. Journal of Surgical Oncology. https://doi.org/10.1002/jso.28005
Vancouver
Bakillah E, Rosenthal JW, Syvyk S, Wirtalla C, Sharpe J, Merchant RM, et al. Colorectal Cancer and Quality of Life: A Medicare Advantage Study by Race, Ethnicity, and Language. Journal of Surgical Oncology. 2025. doi:10.1002/jso.28005
BibTeX
@article{Bakillah2025,
author = {Bakillah, Emna and Rosenthal, J Walker and Syvyk, Solomiya and Wirtalla, Chris and Sharpe, James and Merchant, Raina M and Mehta, Shivan J and Guerra, Carmen E and Kelz, Rachel},
title = {Colorectal Cancer and Quality of Life: A Medicare Advantage Study by Race, Ethnicity, and Language},
journal = {Journal of Surgical Oncology},
year = {2025},
doi = {10.1002/jso.28005}
}
EUVIMED